2025 · 1st Quarter (Jan 1 - Mar 31)

PFIZER, INC.

Filed by MARSHALL & POPP, LLC.

Open official filing

Source-reported fields

Filing overview

Type: 1st Quarter - Report
Posted: Apr 21, 2025
Income: $60,000.00
Expenses: Not reported
Registrant: MARSHALL & POPP, LLC
Client: PFIZER, INC.
Filing UUID: bc0c64eb-3753-4cc8-9e8c-8ed9312c790e
Termination date: Not reported

Literal source text

Lobbying issues and bill citations

BUD · Budget/Appropriations

Issues related to budget reconciliation, including H.Con.Res. 14 and S.Con.Res. 7.

Literal federal measure citations: H.Con.Res. 14, S.Con.Res. 7

PHA · Pharmacy

Issues related to prescription drug value, including H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; and implementation of the Inflation Reduction Act (PL 117-169). Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including H.R. 2882, FY2024 Further Consolidated Appropriations Act. Issues related to the 340B program.

Literal federal measure citations: H.R. 1492, H.R. 2882

CPT · Copyright/Patent/Trademark

Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041; Affordable Prescriptions for Patients Act.

Literal federal measure citations: S.1040, S.1041

TRD · Trade (domestic/foreign)

Issues related to tariff and trade policy.

TAX · Taxation/Internal Revenue Code

Issues related to vaccine excise taxes and the Vaccine Injury Compensation Fund.

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.